Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

Next Previous
X
Search
Trial Profile

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarecycline (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Acronyms PROSES
  • Sponsors Almirall S.A.

    • Most Recent Events

    • 12 Mar 2024 Results of Safety of sarecycline presented at the American Academy of Dermatology annual Meeting 2024
    • 21 Mar 2023 Results evaluating facial IGA and the associated IGA success, stratified by race and baseline AV severity, among AV patients administered sarecycline in community practices across the U.S, presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Oct 2022 According to an Almirall media release, data from this study will be publishing in a peer-reviewed journal by the end of this year 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top